Genotyping low-grade gliomas among Hispanics

Low-grade gliomas (LGGs) are classified by the World Health Organization as astrocytoma (DA), oligodendroglioma (OD), and mixed oligoastrocytoma (OA). TP53 mutation and 1p19q codeletion are the most-commonly documented molecular abnormalities. Isocitrate dehydrogenase (IDH) 1/2 mutations are frequen...

Full description

Autores:
Cardona-Mendoza, Andrés Felipe
Rojas Puentes, Leonardo
Wills, Beatriz
Behaine, José
Jiménez, Enrique
Hakim, Fernando
Useche, Nicolás
Bermúdez, Sonia
Arrieta, Oscar
Mejía, Juan Armando
Ramón, Juan Fernando
Carranza Isaza, Hernán
Vargas Báez, Carlos Alberto
Otero, Jorge
González, Diego
Rodríguez, July
Ortiz, León Darío
Cifuentes, Hernando
Balaña, Carmen
Tipo de recurso:
Article of journal
Fecha de publicación:
2016
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/4494
Acceso en línea:
http://hdl.handle.net/20.500.12495/4494
https://doi.org/10.1093/nop/npv061
Palabra clave:
Biomarcador
Gliomas de bajo grado
Perfil molecular
Pronóstico
Biomarker
Hispanics
low-grade gliomas
Molecular profile
Prognosis
Rights
openAccess
License
Acceso abierto
id UNBOSQUE2_711f32c668ddb3fb220e670d009bb6b3
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/4494
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Genotyping low-grade gliomas among Hispanics
dc.title.translated.spa.fl_str_mv Genotyping low-grade gliomas among Hispanics
title Genotyping low-grade gliomas among Hispanics
spellingShingle Genotyping low-grade gliomas among Hispanics
Biomarcador
Gliomas de bajo grado
Perfil molecular
Pronóstico
Biomarker
Hispanics
low-grade gliomas
Molecular profile
Prognosis
title_short Genotyping low-grade gliomas among Hispanics
title_full Genotyping low-grade gliomas among Hispanics
title_fullStr Genotyping low-grade gliomas among Hispanics
title_full_unstemmed Genotyping low-grade gliomas among Hispanics
title_sort Genotyping low-grade gliomas among Hispanics
dc.creator.fl_str_mv Cardona-Mendoza, Andrés Felipe
Rojas Puentes, Leonardo
Wills, Beatriz
Behaine, José
Jiménez, Enrique
Hakim, Fernando
Useche, Nicolás
Bermúdez, Sonia
Arrieta, Oscar
Mejía, Juan Armando
Ramón, Juan Fernando
Carranza Isaza, Hernán
Vargas Báez, Carlos Alberto
Otero, Jorge
González, Diego
Rodríguez, July
Ortiz, León Darío
Cifuentes, Hernando
Balaña, Carmen
dc.contributor.author.none.fl_str_mv Cardona-Mendoza, Andrés Felipe
Rojas Puentes, Leonardo
Wills, Beatriz
Behaine, José
Jiménez, Enrique
Hakim, Fernando
Useche, Nicolás
Bermúdez, Sonia
Arrieta, Oscar
Mejía, Juan Armando
Ramón, Juan Fernando
Carranza Isaza, Hernán
Vargas Báez, Carlos Alberto
Otero, Jorge
González, Diego
Rodríguez, July
Ortiz, León Darío
Cifuentes, Hernando
Balaña, Carmen
dc.contributor.orcid.none.fl_str_mv Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
Carranza Isaza, Hernán [0000-0002-3593-7405]
Vargas Báez, Carlos Alberto [0000-0002-6076-8260]
Rojas Puentes, Leonardo [0000-0002-7865-5424]
dc.subject.decs.spa.fl_str_mv Biomarcador
Gliomas de bajo grado
Perfil molecular
Pronóstico
topic Biomarcador
Gliomas de bajo grado
Perfil molecular
Pronóstico
Biomarker
Hispanics
low-grade gliomas
Molecular profile
Prognosis
dc.subject.keywords.spa.fl_str_mv Biomarker
Hispanics
low-grade gliomas
Molecular profile
Prognosis
description Low-grade gliomas (LGGs) are classified by the World Health Organization as astrocytoma (DA), oligodendroglioma (OD), and mixed oligoastrocytoma (OA). TP53 mutation and 1p19q codeletion are the most-commonly documented molecular abnormalities. Isocitrate dehydrogenase (IDH) 1/2 mutations are frequent in LGGs; however, IDH-negative gliomas can also occur. Recent research suggests that ATRX plays a significant role in gliomagenesis. We investigated p53 and Olig2 protein expression, and MGMT promoter methylation, 1p19q codeletion, IDH, and ATRX status in 63 Colombian patients with LGG. The overall survival (OS) rate was estimated and compared according to genotype. The most common histology was DA, followed by OD and OA. IDH1/2 mutations were found in 57.1% and MGMT+ (positive status of MGMT promoter methylation methyl-guanyl-methyl-transferase gene) in 65.1% of patients, while overexpression of p53 and Olig2 was present in 30.2% and 44.4%, respectively, and 1p19q codeletion in 34.9% of the patients. Overexpression of ATRX was analyzed in 25 patients, 16% tested positive and were also mutations in isocitrate dehydrogenase and negative 1p19q-codelition. The median follow-up was 15.8 months (95% CI, 7.6–42.0) and OS was 39.2 months (95% CI, 1.3–114). OS was positively and significantly affected by MGMT+, 1p19q codeletion, surgical intervention extent, and number of lobes involved. Multivariate analysis confirmed that MGMT methylation status and 1p19q codeletion affected OS. This is the first study evaluating the molecular profile of Hispanic LGG patients. Findings confirmed the prognostic relevance of MGMT methylation and 1p19q codeletion, but do not support IDH1/2 mutation as a relevant marker. The latter may be explained by sample size and selection bias. ATRX alterations were limited to patients with DA and were mutations in isocitrate dehydrogenase and negative 1p19q-codelition.
publishDate 2016
dc.date.issued.none.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2020-10-21T20:03:00Z
dc.date.available.none.fl_str_mv 2020-10-21T20:03:00Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 2054-2585
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/4494
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1093/nop/npv061
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 2054-2585
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/4494
https://doi.org/10.1093/nop/npv061
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Neuro-Oncology Practice, 2054-2585, Vol. 3, No. 3, 2016, p. 164-172
dc.relation.uri.none.fl_str_mv https://academic.oup.com/nop/article/3/3/164/2238246
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
dc.rights.creativecommons.none.fl_str_mv 2016-09
rights_invalid_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
2016-09
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Oxford University Press
dc.publisher.journal.spa.fl_str_mv Neuro-Oncology Practice
institution Universidad El Bosque
bitstream.url.fl_str_mv https://repositorio.unbosque.edu.co/bitstreams/ba867aa2-68d8-473b-9f61-477610af107d/download
https://repositorio.unbosque.edu.co/bitstreams/813938fe-29a4-401e-acdc-bc2fae60a67d/download
https://repositorio.unbosque.edu.co/bitstreams/eee66c59-2f2d-4379-bc4d-7acc02c211d3/download
https://repositorio.unbosque.edu.co/bitstreams/935d8ffd-7092-4fe1-8883-2555a6deb20f/download
bitstream.checksum.fl_str_mv b2d3d6543bc39cd7e64392011807e01b
8a4605be74aa9ea9d79846c1fba20a33
c7eb50dd4ef8fe0d9a5cb847c84bf698
e3f66790e80b42163faa8b6f876dbd8f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814100733656563712
spelling Cardona-Mendoza, Andrés FelipeRojas Puentes, LeonardoWills, BeatrizBehaine, JoséJiménez, EnriqueHakim, FernandoUseche, NicolásBermúdez, SoniaArrieta, OscarMejía, Juan ArmandoRamón, Juan FernandoCarranza Isaza, HernánVargas Báez, Carlos AlbertoOtero, JorgeGonzález, DiegoRodríguez, JulyOrtiz, León DaríoCifuentes, HernandoBalaña, CarmenCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]Carranza Isaza, Hernán [0000-0002-3593-7405]Vargas Báez, Carlos Alberto [0000-0002-6076-8260]Rojas Puentes, Leonardo [0000-0002-7865-5424]2020-10-21T20:03:00Z2020-10-21T20:03:00Z20162054-2585http://hdl.handle.net/20.500.12495/4494https://doi.org/10.1093/nop/npv061instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengOxford University PressNeuro-Oncology PracticeNeuro-Oncology Practice, 2054-2585, Vol. 3, No. 3, 2016, p. 164-172https://academic.oup.com/nop/article/3/3/164/2238246Genotyping low-grade gliomas among HispanicsGenotyping low-grade gliomas among HispanicsArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85BiomarcadorGliomas de bajo gradoPerfil molecularPronósticoBiomarkerHispanicslow-grade gliomasMolecular profilePrognosisLow-grade gliomas (LGGs) are classified by the World Health Organization as astrocytoma (DA), oligodendroglioma (OD), and mixed oligoastrocytoma (OA). TP53 mutation and 1p19q codeletion are the most-commonly documented molecular abnormalities. Isocitrate dehydrogenase (IDH) 1/2 mutations are frequent in LGGs; however, IDH-negative gliomas can also occur. Recent research suggests that ATRX plays a significant role in gliomagenesis. We investigated p53 and Olig2 protein expression, and MGMT promoter methylation, 1p19q codeletion, IDH, and ATRX status in 63 Colombian patients with LGG. The overall survival (OS) rate was estimated and compared according to genotype. The most common histology was DA, followed by OD and OA. IDH1/2 mutations were found in 57.1% and MGMT+ (positive status of MGMT promoter methylation methyl-guanyl-methyl-transferase gene) in 65.1% of patients, while overexpression of p53 and Olig2 was present in 30.2% and 44.4%, respectively, and 1p19q codeletion in 34.9% of the patients. Overexpression of ATRX was analyzed in 25 patients, 16% tested positive and were also mutations in isocitrate dehydrogenase and negative 1p19q-codelition. The median follow-up was 15.8 months (95% CI, 7.6–42.0) and OS was 39.2 months (95% CI, 1.3–114). OS was positively and significantly affected by MGMT+, 1p19q codeletion, surgical intervention extent, and number of lobes involved. Multivariate analysis confirmed that MGMT methylation status and 1p19q codeletion affected OS. This is the first study evaluating the molecular profile of Hispanic LGG patients. Findings confirmed the prognostic relevance of MGMT methylation and 1p19q codeletion, but do not support IDH1/2 mutation as a relevant marker. The latter may be explained by sample size and selection bias. ATRX alterations were limited to patients with DA and were mutations in isocitrate dehydrogenase and negative 1p19q-codelition.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2016-09ORIGINALCardona_Andrés_Felipe_2016.pdfCardona_Andrés_Felipe_2016.pdfapplication/pdf271764https://repositorio.unbosque.edu.co/bitstreams/ba867aa2-68d8-473b-9f61-477610af107d/downloadb2d3d6543bc39cd7e64392011807e01bMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/813938fe-29a4-401e-acdc-bc2fae60a67d/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILCardona_Andrés_Felipe_2016.pdf.jpgCardona_Andrés_Felipe_2016.pdf.jpgIM Thumbnailimage/jpeg10820https://repositorio.unbosque.edu.co/bitstreams/eee66c59-2f2d-4379-bc4d-7acc02c211d3/downloadc7eb50dd4ef8fe0d9a5cb847c84bf698MD53TEXTCardona_Andrés_Felipe_2016.pdf.txtCardona_Andrés_Felipe_2016.pdf.txtExtracted texttext/plain48617https://repositorio.unbosque.edu.co/bitstreams/935d8ffd-7092-4fe1-8883-2555a6deb20f/downloade3f66790e80b42163faa8b6f876dbd8fMD5420.500.12495/4494oai:repositorio.unbosque.edu.co:20.500.12495/44942024-02-07 01:29:34.428restrictedhttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.comTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=